Candel reports extended survival in Phase II CAN-2409 trial

26 February 2025

Candel Therapeutics (Nasdaq: CADL) has released final data from a Phase II trial of its investigational immunotherapy, CAN-2409, in non-metastatic pancreatic ductal adenocarcinoma (PDAC), showing a notable survival benefit.

The study found that patients treated with CAN-2409 had a median overall survival of 31.4 months, compared to 12.5 months for those receiving standard treatment alone. Despite the findings, Candel stock fell more than 20% following the announcement, reflecting investor uncertainty over the relative strength of the data.

The randomized controlled trial evaluated CAN-2409 in combination with GSK’s (LSE: GSK) Valtrex (valacyclovir) alongside standard-of-care chemoradiation therapy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK